All News

“Our group all felt that we were caught off guard," said one urologist about the AUA's new prostate cancer screening guideline.

A relatively new imaging system demonstrates a higher capacity for mapping recurrent prostate cancer than integrated positron emission tomography and computed tomography, researchers recently reported at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Vancouver, British Columbia.

The use of computed tomography scans of the head, abdomen/pelvis, chest, or spine in children younger than 14 years of age more than doubled from 1996 to 2005, according to a study of seven U.S. health care systems.

Men with prostate cancer may significantly improve their survival chances with a simple change in their diet, according to a recent study.

AVEO Oncology recently announced that it has received a complete response letter from the FDA informing the company that the FDA will not approve in its present form the new drug application for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.

A new AUA guideline on the early detection of prostate cancer is a PSA-focused, evidence-based guideline intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening in order to reduce prostate cancer mortality, said H. Ballentine Carter, MD, at the AUA annual meeting in San Diego.

Results from the primary endpoint analysis in a phase III randomized, placebo-controlled study showed that intravenous radium Ra 223 dichloride (Xofigo), an alpha-particle-emitting radiotherapeutic agent and calcium mimetic that binds to newly formed bone stroma, significantly improved overall survival in castration-resistant prostate cancer patients with bone metastases.

The prevalence of urolithiasis in the United States and the cost of its care will increase dramatically in the future if the epidemics of obesity and diabetes mellitus continue unchecked, according to analyses conducted by researchers at the University of Texas Southwestern Medical Center, Dallas.

Among the various choices for saving for college, attention seems to be focused on the section 529 plan.

The complicated landscape of federal and private insurance, fraud and abuse laws, and anti-kickback statutes have created new context for “professional courtesy,” and physicians should be aware of the applicable rules and regulations that could apply to this once-common practice.

Typically, a consultant is brought into a urology practice for a particular project such as conducting an operational assessment, but just as importantly, once the consultant has gained this familiarity with the practice, he/she makes a great mentor.

The AUA has released its first-ever clinical practice guideline for castration-resistant prostate cancer, and all urologists who care for men with advanced prostate cancer should familiarize themselves with its contents, said Michael S. Cookson, MD, who presented the new guideline at the AUA annual meeting in San Diego.

Resources to help you understand the current state of the urology work force, including trends specific to your county, and future projections. Watch for updates to this page as they become available!

A novel class of drug that disrupts androgen receptor signaling may some day provide a new therapeutic option for patients with advanced prostate cancer who fail androgen blockade.

Researchers using next-generation genomic analysis have determined that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression.

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

Lenox Hill Hospital, New York has announced the appointment of David B. Samadi, MD, as chair of urology at Lenox Hill Hospital and professor of urology at the Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, NY.

Sir David Innes Williams, MD, MChir, who is credited with founding the specialty of pediatric urology, has died. He was 93.

The recent completion of the AUA’s Guideline on Castration-Resistant Prostate Cancer was not only timely but also very important for those of us treating these patients.

Recent studies examining the broad impact of the aging population suggest an increasing demand on the overall urology work force, which, when coupled with a changing work force demographic, predicts a significant shortage that is only likely to worsen.

Attendees of the 2013 AUA annual meeting offer their take on the urologist shortage and what should be done about it.

A national crisis over huge Veterans Administration backlogs in providing medical benefits to soldiers returning from Afghanistan and Iraq may be providing the platform for congressional consideration of legislation aimed at addressing urotrauma injuries incurred in combat.

Researchers are predicting that the number of urologists in the United States will fall sharply over the next 12 years, dropping by almost 30% by 2025 compared to 2009.

Attendees of the 2013 AUA annual meeting offer their take on the urologist shortage and what should be done about it.

The latest urology products and services from Olympus; Augmenix, Inc.; Cook Medical; SonaCare Medical; and Sony Electronics' Medical Systems Division.

In this interview, Christopher M. Gonzalez, MD, MBA, discusses the scope of the urology work force problem, the impact of graduate medical education funding caps, and possible long- and short-term solutions.

A recent analysis has found a link between exposure to the herbicide known as Agent Orange and lethal forms of prostate cancer among U.S. veterans.

The AUA has voiced its support for proposed legislation that would change the way the U.S. Preventive Services Task Force makes its recommendations.

Physicians and patients alike may not be aware of the benefits of nephron-sparing surgical methods, according to a recent study.

In what is being called the largest clinical trial to examine the efficacy of poly(ADP-ribose) polymerases (PARP) inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced forms of both prostate and pancreatic cancer.